Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshihide Nishishita is active.

Publication


Featured researches published by Toshihide Nishishita.


Journal of Biological Chemistry | 1996

The Interaction between Ku Antigen and REF1 Protein Mediates Negative Gene Regulation by Extracellular Calcium

Ung-il Chung; Tetsuya Igarashi; Toshihide Nishishita; Hiroko Iwanari; Akihiro Iwamatsu; Akira Suwa; Tsuneyo Mimori; Keishi Hata; Shogo Ebisu; Etsuro Ogata; Toshiro Fujita; Tomoki Okazaki

Through the specific binding of a negative calcium-responsive element to its binding protein in response to extracellular Ca (Ca), negative calcium-responsive element-bearing genes, such as the human parathyroid hormone gene, are negatively regulated by Ca. The Ku antigen mediated negative gene regulation by Ca by interacting with a redox factor protein, REF1. Although sequence-nonspecific DNA binding activity of the Ku antigen has been well characterized, the mechanism of its sequence-specific DNA binding remained obscure. Here, we report that the specific binding of the Ku antigen to another protein, REF1, leads to DNA-protein complex formation with a novel sequence specificity and thereby regulates gene expression.


Journal of Biological Chemistry | 1998

A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D.

Toshihide Nishishita; Tomoki Okazaki; Toshio Ishikawa; Tetsuya Igarashi; Keishi Hata; Etsuro Ogata; Toshiro Fujita

We found that the human parathyroid hormone-related peptide (hPTHrP) gene contained a DNA element (nVDREhPTHrP) homologous to a negative vitamin D response element in the human parathyroid hormone gene. It bound to vitamin D receptor (VDR) but not retinoic acid Xα receptor (RXRα) in the human T cell line MT2 cells. VDR binding to this element was confirmed by the Southwestern assay combined with immunodepletion using anti-VDR monoclonal antibody, and this binding activity was repressed by 1,25-dihydroxyvitamin D3. Such a repression was reversed by acid phosphatase treatment, suggesting that 1,25-dihydroxyvitamin D3 phosphorylates VDR to weaken its binding activity to nVDREhPTHrP. In electrophoretic mobility shift assay, we found anti-Ku antigen antibody specifically supershifted the MT2 nuclear proteinnVDREhPTHrP complex. The nVDREhPTHrP-bearing reporter plasmid produced vitamin D-dependent inhibition of the reporter activity in MT2 cells, which was markedly masked by the introduction of the Ku antigen expression vector in the antisense orientation. On the other hand, such a procedure did not perturb the vitamin D response element-mediated gene stimulation by vitamin D. These results indicate that nVDREhPTHrP interacts with Ku antigen in addition to VDR to mediate gene suppression by vitamin D.


Clinical Cancer Research | 2005

Carbonic Anhydrase II Is a Tumor Vessel Endothelium ^ Associated Antigen Targeted by Dendritic Cell Therapy

Kenta Yoshiura; Takashi Nakaoka; Toshihide Nishishita; Katsuaki Sato; Akifumi Yamamoto; Shinji Shimada; Toshiaki Saida; Yutaka Kawakami; Tsuneo A. Takahashi; Hiroyuki Fukuda; Shinobu Imajoh-Ohmi; Naoki Oyaizu; Naohide Yamashita

Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium–associated antigen in melanoma and other cancers, and elicitation of serum anti–CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction.


Journal of Experimental & Clinical Cancer Research | 2009

Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line

Kenta Yoshiura; Toshihide Nishishita; Takashi Nakaoka; Naohide Yamashita; Naomi Yamashita

BackgroundKey role of angiogenesis in tumor growth and metastasis based on accumulating evidence and recent progress of immunotherapy have led us to investigate vaccine therapy targeting tumor angiogenesis.MethodsC57BL/6J mice were vaccinated with a syngeneic endothelial cell line Tpit/E by subcutaneous injection once a week. Prior to ninth vaccination, the mice were challenged with B16/F10 melanoma cells by subcutaneous inoculation on the back for the tumor growth model or by tail venous injection for the lung metastasis model. Development of subcutaneous tumor and lung metastasis was monitored by computed tomography scanning, which enabled accurate evaluation with the minimized sacrifice of mice.ResultsVaccination with Tpit/E cells inhibited subcutaneous tumor growth and appearance of lung metastasis compared to control. Survival period was elongated in the Tpit/E vaccination in both of the two models. We also obtained hybridomas secreting specific antibodies to Tpit/E cells from a mouse vaccinated with the cells, indicating that specific immune response to the syngeneic endothelial cells was elicited.ConclusionThese results suggest that vaccination with an autologous endothelial cell line may be effective against melanoma.


Journal of Molecular Endocrinology | 2007

Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers

Misa Nakamura; Bo Han; Toshihide Nishishita; Yanhua Bai; Kennichi Kakudo

The mitogen-activated protein kinases (MAPKs) signaling pathway is a potential target in cancer therapy. Constitutive phosphorylated extracellular signal-regulated kinase (ERK1/2), which is one of the MAPKs has been detected in a variety of tumors. Calcitonin (CT) is a polypeptide hormone secreted by the thyroid gland and has been used to treat the osteoporosis and humoral hypercalcemia of malignancy. We report that CT decreases ERK1/2 phosphorylation in cancer cells showing constitutive phosphorylated ERK1/2. In MDA-MB-231 cells, a breast cancer cell line showing constitutive phosphorylated ERK1/2, CT phosphorylated c-Raf at Ser(259) via the protein kinase A pathway, resulting in suppression of ERK1/2 phosphorylation. CT significantly reduced the tumor volume of MDA-MB-231 cells showing constitutive phosphorylated ERK1/2 compared with saline buffer. However, CT did not exert any significant effects on the proliferation of MCF-7 cells, a breast cancer cell line, showing non-constitutive phosphorylated ERK1/2. These novel findings indicate that CT may be used to target ERK in the treatment of cancer.


Microbiology and Immunology | 2003

Efficient adeno-associated virus-mediated gene expression in human placenta-derived mesenchymal cells

Xiaohong Zhang; Takashi Nakaoka; Toshihide Nishishita; Nobukazu Watanabe; Koichi Igura; Kenichi Shinomiya; Tsuneo A. Takahashi; Naohide Yamashita

Mesenchymal cells from various sources are pluripotent and are attractive sources for cell transplantation. In this study, we analyzed recombinant adeno‐associated virus (rAAV)‐mediated gene expression in human placenta‐derived mesenchymal cells (hPDMCs), which reside in placental villi. After transduction of AV‐CAG‐EGFP, a rAAV expressing enhanced green fluorescence protein (EGFP), hPDMCs showed much higher level of EGFP expression than human umbilical vein endothelial cells or rat aortic smooth muscle cells. The number of EGFP‐positive hPDMCs infected by AV‐CAG‐EGFP alone did not increase significantly by coinfection of adenovirus, which enhanced expression level of the rAAV vector. Moreover, flow cytometric analysis showed discrete positive fraction of EGFP‐expressing hPDMCs, which is about 15–20% of the cells infected with AV‐CAG‐EGFP. Therefore, some cell population in hPDMCs might be highly susceptible to rAAV‐mediated gene transduction. In addition, stable EGFP expressions were observed in about 1% of hPDMCs infected with AV‐CAG‐EGFP at 4 weeks post‐infection. Collectively, hPDMCs have characters favorable for rAAV‐mediated gene expression.


Journal of Biological Chemistry | 1994

A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium.

Tomoki Okazaki; Ung-il Chung; Toshihide Nishishita; S Ebisu; S Usuda; S Mishiro; S Xanthoudakis; Tetsuya Igarashi; Etsuro Ogata


Biochemical and Biophysical Research Communications | 2004

A potential pro-angiogenic cell therapy with human placenta-derived mesenchymal cells.

Toshihide Nishishita; Kunie Ouchi; Xiaohong Zhang; Mariko Inoue; Takeshi Inazawa; Kenta Yoshiura; Koichiro Kuwabara; Takashi Nakaoka; Nobukazu Watanabe; Koichi Igura; Tsuneo A. Takahashi; Naohide Yamashita


Internal Medicine | 1992

A Patient with Protein-Losing Enteropathy Associated with Systemic Lupus Erythematosus

Ung-il Chung; Masashi Oka; Yasushi Nakagawa; Toshihide Nishishita; Nobuo Sekine; Yuji Tanaka; Shun-ichi Harada; Tetsuya Igarashi; Etsuro Ogata


Endocrinology | 2004

Differential Regulation of Cell Migration and Proliferation through Proline-Rich Tyrosine Kinase 2 in Endothelial Cells

Koichiro Kuwabara; Takashi Nakaoka; Kaori Sato; Toshihide Nishishita; Terukatsu Sasaki; Naohide Yamashita

Collaboration


Dive into the Toshihide Nishishita's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge